Heute plus 18 % - 500 Beiträge pro Seite

[frank55]

Nachricht vom 17.4.2006
Latest News

--------------------------------------------------------------------------------
(Printer friendly version) PharmaFrontiers Completes $23 Million Financing to Advance Therapeutics; Plans Reverse Stock Split

THE WOODLANDS, Texas, Apr 17, 2006 (BUSINESS WIRE) -- PharmaFrontiers Corp. (OTCBB: PFTR), a company involved in the development and commercialization of cell therapies, has raised approximately $23 million in a private placement to institutional and other accredited investors of approximately 23 million units at $1.00 per unit, comprised of two shares of newly issued common stock and a five-year redeemable warrant to purchase one share of common stock at an exercise price of $0.65 per share. MDB Capital Group LLC acted as the exclusive placement agent.
The proceeds will be used primarily to fund PharmaFrontiers' Phase IIb trial with Tovaxin(TM) for the treatment of multiple sclerosis. The Company expects to begin the trial in the second quarter of 2006. The funds will also be used to complete pre-clinical development and initiate human clinical trials of the Company's rheumatoid arthritis and Type 1 diabetes therapies.

In connection with the private placement, PharmaFrontiers has agreed to file a registration statement on Form SB-2 by May 13, 2006 to register the resale of the shares of common stock and the shares underlying the warrants.

In addition, the Company announced that its board of directors has approved, and will recommend to the Company's shareholders for their approval, a one-for-ten reverse stock split. PharmaFrontiers believes this reverse stock split will enable the Company to apply for a listing on Nasdaq.

David B. McWilliams, chief executive officer of PharmaFrontiers, commented, "This additional capital is a tremendous catalyst for the Company and will provide us with the financial resources to implement our clinical program, for both our T-cell and stem cell technologies and to fulfill their potential as life-saving therapies. We believe that the strengthening of our capital structure in connection with the reverse stock split will provide the backbone for a strong organization with prospects for a Nasdaq listing."

About PharmaFrontiers Corp.

PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as multiple sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions. PharmaFrontiers has exclusive license from Baylor College of Medicine for individualized cell therapies that will be starting an FDA Phase IIb clinical trial to evaluate effectiveness in treating MS. The company also holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The company also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood.

About MDB Capital Group LLC

MDB Capital Group is a research driven investment bank providing financial services to emerging growth companies, as well as institutional asset management firms, mutual funds, hedge funds and high net worth individuals.

Founded in 1997, MDB provides the following professional services:

-- Equity Research

-- Equity Sales and Trading

-- Investment Banking

-- Fixed Income Sales and Trading

MDB is an NASD licensed broker-dealer and a member of the Securities Investor Protection Corporation ("SIPC"). MDB is based in Santa Monica, CA with an office in New York City.

Safe Harbor Statement

his press release contains "forward-looking statements," including statements about PharmaFrontiers' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to PharmaFrontiers' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause PharmaFrontiers' actual results to be materially different from any future results expressed or implied by such forward-looking statements. PharmaFrontiers undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: PharmaFrontiers Corp.


CONTACT: PharmaFrontiers Corp. Lynne Hohlfeld, 281-719-3421 [e-mail] or Investor Relations Contacts: Lippert/Heilshorn & Associates Kim Sutton Golodetz, 212-838-3777 [e-mail] or Bruce Voss, 310-691-7100 [e-mail]


Copyright Business Wire 2006



KEYWORD: United States

North America

Texas

INDUSTRY KEYWORD: Health

Biotechnology

Clinical Trials

Pharmaceutical

Research & Science

Other Health

Professional Services

Banking

Finance

SUBJECT CODE: Funding

[frank55]

0.84 pftr - PHARMAFRONTIERS CORP
Change:

+0.19 % Change:

+29.23% High:

0.85 Low:

0.65 Volume:

177,640

Price Data Table
Open 0.65
Previous Close 0.84
Exchange of Last Sale OTCBB
Time of Last Sale 13:53:46
Tick Up
Bid 0.82
Ask
Size Bid/Ask 25x25
Symbol Type Equity

Fundamental Data Table
52 Week High 5.50
52 Week Low 0.30
EPS -1.24
P/E Ratio 0.00
Shares Outstanding 52,000,000

Explosiv

[frank55]

0.88 pftr - PHARMAFRONTIERS CORP
Change:

+0.23 % Change:

+35.38% High:

0.88 Low:

0.65 Volume:

187,740

Price Data Table
Open 0.65
Previous Close 0.88
Exchange of Last Sale OTCBB
Time of Last Sale 14:00:29
Tick Up
Bid 0.82
Ask
Size Bid/Ask 25x25
Symbol Type Equity

Fundamental Data Table
52 Week High 5.50
52 Week Low 0.30
EPS -1.24
P/E Ratio 0.00
Shares Outstanding 49,000,000
Market Cap 43,529,000
Beta 2.053
Dividend Frequency
Ex-Dividend Date
Dividend Amount

Unglaublich

[frank55]

0.92 pftr - PHARMAFRONTIERS CORP
Change:

+0.07 % Change:

+8.24% High:

0.92 Low:

0.85 Volume:

17,390

Price Data Table
Open 0.87
Previous Close 0.92
Exchange of Last Sale OTCBB
Time of Last Sale 12:25:09
Tick Up
Bid 0.87
Ask
Size Bid/Ask 25x25
Symbol Type Equity

Fundamental Data Table
52 Week High 5.50
52 Week Low 0.30
EPS -1.24
P/E Ratio 0.00
Shares Outstanding 62,000,000
Market Cap 56,922,000
Beta 2.053
Dividend Frequency
Ex-Dividend Date
Dividend Amount
Yield 0.00
Primary Exchange OTCBB

Es geht weiter mit grossen Schritten und kleinen Umsätzen nach oben

[Realist5]

Tovaxin to be presented by PharmaFrontiers
by multiplesclerosis on Fri 31 Mar 2006 03:00 AM CST | Permanent Link | Cosmos
PharmaFrontiers to Present Tovaxin(TM)

Research at Consortium of Multiple Sclerosis Centers' Annual Meeting


THE WOODLANDS, Texas--(BUSINESS WIRE)—



PharmaFrontiers Corp, a company involved in the development and commercialization of cell therapies, announced today that its paper entitled, "Autologous Trivalent T Cell Therapy in Multiple Sclerosis: A Study of Patients Previously Treated with Monovalent T Cell Therapy," (monovalent = containing only one kind of antibody) has been accepted for a platform presentation at the 20th Consortium of Multiple Sclerosis Centers' Annual Meeting to be held on May 31 to June 3, 2006 in Scottsdale, Arizona. Brian Loftus, M.D., Diagnostic Clinic of Houston, and the Company's lead clinical investigator, will make the presentation.

The objective of the study was to evaluate the safety, effectiveness and tolerability of Tovaxin in patients with relapsing remitting and secondary progressive multiple sclerosis (MS) who had previously received a monovalent autologous T cell therapy formulated with only myelin basic protein (MBP) reactive T cells. Tovaxin(TM) is a trivalent formulation of attenuated myelin-peptide reactive T cells (MRTCs); which are derived from peripheral blood and produced ex vivo as MBP, proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG) reactive T cells. The interim trial results indicate that the therapy appears to be safe, effective and well tolerated as a re-treatment vaccination therapy.

"The positive therapeutic effects of safety, early effectiveness, and tolerability observed in this extension study suggest that depletion of MRTCs using a trivalent formulation may be an appropriate re-treatment strategy for long-term effectiveness in patients with MS," said David B. McWilliams, chief executive officer of PharmaFrontiers.

In the extension study, ten patients were treated with the trivalent vaccine. The results demonstrated the ability of Tovaxin to deplete the peripheral blood MRTCs which are believed to play a critical role in the pathogenesis of MS. Forty percent (40%) of the patients in the trial had improvements in the Kurtzke Expanded Disability Status Scale (EDSS), which is an objective measure of the patient's physical disability and none of the patients had worsening disease.

"Combined with the data presented at ECTRIMS 2005, we have now demonstrated the ability of T-cell vaccination to deplete MRTCs in both previously vaccinated and previously unvaccinated subjects," said Brian Loftus, M.D. "Proving that the reduction in peripheral blood MRTCs reduces MS attacks will be the focus of a Phase IIb study beginning 2nd quarter 2006."

"In our upcoming double-blind placebo-controlled Phase IIb clinical trial, named TERMS (Tovaxin for Early Relapsing Multiple Sclerosis), patients with clinically isolated syndrome and relapse-remitting MS, the most common presenting form of MS, will be treated in a one year study followed by an open-label longitudinal follow-up study to assess long-term safety and effectiveness," said Jim C. Williams, Ph.D., chief operating officer of PharmaFrontiers. "The information obtained in the Phase IIb clinical trial will provide the information to plan a Phase III trial."

About PharmaFrontiers Corp.

PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as cardiac and pancreatic conditions, Multiple Sclerosis and rheumatoid arthritis. PharmaFrontiers owns patented and proprietary individualized cell therapies that are in FDA Phase I/II human dose ranging clinical trials to evaluate their safety and effectiveness in treating MS. The company also holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The company also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about PharmaFrontiers' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to PharmaFrontiers' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause PharmaFrontiers' actual results to be materially different from any future results expressed or implied by such forward-looking statements. PharmaFrontiers undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

[Realist5]

Aussichtsreicher Wirkstoff, neues Kapital und ein mögliches Nasdaq-Listing. Klingt vielversprechend. Aber wohl auch viel Risiko.
52 Wochen-Hoch ist bei 5,52 USD. Die Aktie war sogar mal bei ca. 14 USD...

[frank55]

Antwort auf Beitrag Nr.: 21.402.245 von Realist5 am 02.05.06 14:30:18

Richtig,das Risiko ist extrem hoch genauso wie die Chancen aber das ist normal bei einer Mantelspekulation,sie haben aber das Geld für einen nomalen Börsengang gespart,hier hat mal die Chance von Anfang an dabei zu sein und nicht,wenn sich die jeweilige Aktie schon verzehnt- oder verdreissigfacht hat

[frank55]

PHARMAFRONTIERS CORP - Nasdaq OTC BB: PFTR

Real-time ECN Quote*
Last Change (%) After Hours Chg (%)** Trade Time Bid Ask
-- -- -- -- -- --




--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
0.96 0.04 (4.35) 13:09 0.93 (25) 0.96 (25)
Latest Ticks Prev Close Open Low High
+-++ 0.92 0.92 0.83 0.96
Day Volume Avg Day Vol VWAP 52 Wk Low 52 Wk High
34,350 48,200 0.9096 0.30 5.50
# of Trades Last Size Avg Trade Size P/E Ratio Market Cap (mil)
19 300 1,808 0 20
1:38:59 PM EDT - Tuesday, May 2, 2006- Exchange quote is delayed at least 15 minutes.


Es geht weiter nach oben,geringe Umsätze,grosse Kurssteigerungen

[frank55]

PharmaFrontiers Names Lynne Hohlfeld Vice President of Finance

THE WOODLANDS, Texas, May 03, 2006 (BUSINESS WIRE) -- PharmaFrontiers Corp. (OTCBB: PFTR), a company involved in the development and commercialization of cell therapies, has announced that Lynne Hohlfeld has joined the Company as vice president of finance.
A certified public accountant, Ms. Hohlfeld brings more than twenty years of diversified public and private company financial experience to PharmaFrontiers. From 2004 until joining PharmaFrontiers in April 2006, she was vice president and chief financial officer of Denota Ventures in The Woodlands, Texas, managing a diverse portfolio of investments.

Ms. Hohlfeld has a particular expertise in the life sciences field. From 2000 to 2004 she served as senior vice president, chief financial officer of Bacterial Barcodes, Inc., a Houston-based molecular diagnostics company spun out of the Baylor College of Medicine there. She was also senior vice president and chief financial officer of Spectral Genomics of Houston upon its merger with Bacterial Barcodes in 2004. Ms. Hohlfeld was also employed by LifeCell Corporation in The Woodlands from 1997 to 1999, serving as controller. Ms. Hohlfeld's career includes positions at Dixie Chemical Company, Price Waterhouse Coopers, McKenna & Company, and Arthur Andersen. Ms. Hohlfeld received a B.B.A. in accounting from the University of Wisconsin - Madison.

David McWilliams, chief executive officer of PharmaFrontiers, stated, "Lynne's extensive experience running the finance and fund-raising operations of multiple life-science companies will be an invaluable asset to PharmaFrontiers. Her public company reporting knowledge and history of dealing with investors and shareholders will be an asset, especially in view of the current regulatory environment. We feel very fortunate to have secured her talents to further strengthen our management team."

About PharmaFrontiers Corp.

PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as multiple sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions. PharmaFrontiers has exclusive license from Baylor College of Medicine for individualized cell therapies that will be starting an FDA Phase IIb clinical trial to evaluate effectiveness in treating MS. The company also holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The company also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood.

For more information, visit PharmaFrontiers' website at www.pharmafrontierscorp.com.

Safe Harbor Statement

his press release contains "forward-looking statements," including statements about PharmaFrontiers' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to PharmaFrontiers' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause PharmaFrontiers' actual results to be materially different from any future results expressed or implied by such forward-looking statements. PharmaFrontiers undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: PharmaFrontiers Corp.


CONTACT: PharmaFrontiers Corp. Lynne Hohlfeld, 281-719-3421 [e-mail] or Investor Relations Contacts: Lippert/Heilshorn & Associates Kim Sutton Golodetz, 212-838-3777 [e-mail] Bruce Voss, 310-691-7100 [e-mail]


Copyright Business Wire 2006



KEYWORD: United States

North America

Texas

INDUSTRY KEYWORD: Health

Biotechnology

Pharmaceutical

SUBJECT CODE: Personnel

[frank55]

PHARMAFRONTIERS CORP - Nasdaq OTC BB: PFTR

Real-time ECN Quote*
Last Change (%) After Hours Chg (%)** Trade Time Bid Ask
-- -- -- -- -- --




--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size)
1.045 0.095 (10.00) 11:09 1.02 (5) 1.045 (5)
Latest Ticks Prev Close Open Low High
--+= 0.95 0.96 0.95 1.05
Day Volume Avg Day Vol VWAP 52 Wk Low 52 Wk High
103,100 50,800 1.0033 0.30 5.50
# of Trades Last Size Avg Trade Size P/E Ratio Market Cap (mil)
40 5,000 2,578 0 22
11:29:37 AM EDT - Wednesday, May 3, 2006- Exchange quote is delayed at least 15 minutes.


Nun geht es weiter nach oben,Widerstand bei 1 $ geknackt.
Aber auch steigende Umsätze

[Realist5]

Ich glaube, wir haben erst den Anfang der Entwicklung gesehen....

[frank55]

Strategie PharmaFrontiers' ist, Zelle Therapien zu entwickeln und in den Handel zu bringen, um einige Hauptkrankheitbereiche wie Herz- und pankreatische Bedingungen und mehrfache Sklerose zu behandeln. PharmaFrontiers besitzt die patentierten und eigenen individualisierten Zelle Therapien, die FDA Phase I/II in den erstreckenden klinischen Versuchen der menschlichen Dosis sind, zum ihrer Sicherheit und Wirksamkeit auszuwerten, wenn sie MS behandeln. Die Firma hält auch die exklusive weltweite Lizenz von der Universität von Chicago, durch sein Hauptunternehmer-Verhältnis Argonne zum nationalen Labor, denn die Patente in bezug auf den Gebrauch von den pluripotent Stammzellen des Erwachsenen, die von eigenem verteilendem Blut der Patienten abgeleitet werden.

[frank55]

PerkinElmer Appoints Daniel R. Marshak as Chief Scientific Officer; Brings 25 Years of Life Sciences and Business Acumen to Lead Key Growth Initiatives


BOSTON--(BUSINESS WIRE)--May 12, 2006--

PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics markets, today announced the appointment of Dr. Daniel R. Marshak as vice president and chief scientific officer for the Company. Marshak will be responsible for setting the strategic direction of PerkinElmer's research and development functions, and helping drive its growth strategies in the emerging areas of personalized medicine and predictive diagnostics.

Marshak brings more than 25 years of life sciences experience to his position and joins PerkinElmer from Cambrex Corporation (NYSE: CBM) where he served as vice president and chief technology officer. In this role, he led major research and business development initiatives for Cambrex's bioscience units worldwide. Marshak currently serves as an adjunct associate professor at Johns Hopkins University School of Medicine. He is an inventor of six series of patents and author of more than 100 articles and abstracts.

"Daniel is a very accomplished health sciences executive and brings deep scientific experience to our leadership team," said Gregory L. Summe, chairman and chief executive officer of PerkinElmer, Inc. "He has a strong track record of linking research with commercialized business opportunities and we look forward to his leadership in supporting PerkinElmer's growth initiatives."

Marshak holds a Ph.D. from The Rockefeller University in New York, New York, and a Bachelor of Arts degree in Biochemistry & Molecular Biology from Harvard University, Cambridge, Massachusetts. He holds numerous patents in stem cell research, has served on the American Association for the Advancement of Science working group on the Ethics of Stem Cell Research, and currently serves as an advisor to PharmaFrontiers Corp. (OTCBB: PFTR), a cellular therapy company developing treatments for diseases including multiple sclerosis and diabetes, and Ortec International, Inc. (US: ORTN), a leading tissue-engineering and advanced wound care company.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Source: PerkinElmer, Inc.

[frank55]

PharmaFrontiers Reports First Quarter 2006 Results


THE WOODLANDS, Texas--(BUSINESS WIRE)--May 15, 2006--

PharmaFrontiers Corp. (OTCBB: PFTR), a company involved in the development and commercialization of cell therapies, today reported financial results for the quarter ended March 31, 2006.

Highlights of the first quarter of 2006 and recent weeks include:

-- Completion of $23 million financing to fund Phase IIb trial
for Tovaxin(TM) and other clinical programs

-- Reconstitution of board of directors with two new board
members

-- Lynne Hohlfeld, CPA named as vice president of finance
David B. McWilliams, chief executive officer of PharmaFrontiers, commented, "We anticipate starting our Phase IIb trial during the second quarter of this year, so we have moved aggressively to ensure that our financial resources, capital structure and management team are all optimally organized and aligned to support this important milestone in our clinical program. We are ready in every sense to focus our energy and resources on our next stage of development."

Financial Results

The Company reported no revenue for the three months ended March 31, 2006 or in its comparative period the year before. General and administrative expenses during the three months ended March 31, 2006 were $1,075,882, compared with $1,206,715 during the same period in 2005. The decrease in general and administrative expenses is due primarily to a reduction in legal fees associated with patent filings, a lower allocation of facilities costs and overhead now allocated to research and development. This was offset in part by an increase in stock-based compensation expense. In January 1, 2006, we adopted Statement of Financial Accounting Standards No. 123 (revised 2004), "Share-Based Payment," ("SFAS 123R") which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including stock options and restricted stock based on estimated fair values. We elected to adopt the modified prospective transition method as provided by SFAS 123R and, accordingly, prior year results have not been restated. Stock-based compensation expense recognized under SFAS 123R for the three months ended March 31, 2006 was $484,392.

Research and development expenses were $738,450 for the first quarter of 2006, compared with $644,264 for the same period in 2005. The increase is primarily related to an increase in consulting fees related to the rheumatoid arthritis program and a higher allocation of facilities and over costs to research and development due to increased development activities.

Interest expense was $429 for the three months ended March 31, 2006, compared with $1,487,384 for the comparable quarter in 2005. The interest expense during 2005 was due to notes that were outstanding during the first quarter of 2005 which were subsequently converted into equity in June 2005.

PharmaFrontiers had a net loss for the three months ended March 31, 2006 of ($2,224,450) or ($0.11) per share (basic and diluted), compared with a net loss of ($3,747,304) or ($0.37) per share (basic and diluted) for the same period of 2005.

The Company had cash of $1,059,856 as of March 31, 2006 as compared with $2,560,666 as of December 31, 2005. After the close of the first quarter of 2006, the Company completed a private placement of equity, which raised $23,000,000.

About PharmaFrontiers Corp.

PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as multiple sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions. PharmaFrontiers has exclusive license from Baylor College of Medicine for individualized cell therapies that will be starting an FDA Phase IIb clinical trial to evaluate effectiveness in treating MS. The company also holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The company also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood.

For more information, visit PharmaFrontiers' website at www.pharmafrontierscorp.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about PharmaFrontiers' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to PharmaFrontiers' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause PharmaFrontiers' actual results to be materially different from any future results expressed or implied by such forward-looking statements. PharmaFrontiers undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

(Tables to follow)

PHARMAFRONTIERS CORP.
FINANCIAL HIGHLIGHTS
(UNAUDITED)

Three Months Three Months Inception
Ended Ended through
March 31, March 31, March 31,
2006 2005 2006
------------- ------------- -------------
Consolidated Statements of
Operations Data:
Expenses
General and administrative $1,075,882 $1,206,715 $2,279,396
Depreciation and
amortization 432,333 418,315 2,432,362
Research and development 738,450 644,264 13,096,337
Loss on disposal of assets 362 - 480,294
------------- ------------- -------------
Operating Loss (2,247,027) (2,269,294) (18,288,389)

Interest income 19,621 6,930 107,543
Other income 3,385 2,444 33,938
Interest expense (429) (1,487,384) (8,238,408)
------------- ------------- -------------
Net Loss (2,224,450) (3,747,304) (26,385,316)
============= ============= =============


Basic and diluted loss per
share $(0.11) $(0.37) N/A

Weighted average shares
outstanding 20,654,294 10,224,456 N/A


As of As of
March 31, December 31,
2006 2005
------------- -------------
Consolidated Balance Sheet
Data:
Cash and cash equivalents
and prepaid expenses $1,268,344 $2,743,190
Intangible assets 25,846,159 26,130,441
Fixed Assets 549,574 479,996
Other assets 450,943 388,210
------------- -------------
Total assets $28,115,020 $29,741,837
============= =============
Current liabilities $2,363,019 $2,429,776
Common stock 1,048,351 1,030,977
Additional paid in capital 51,088,966 50,441,948
Deficit accumulated during
the development stage (26,385,316) (24,160,864)
------------- -------------
Total stockholders' equity 25,752,001 27,312,061
------------- -------------
Total liabilities and
stockholders' equity $28,115,020 $29,741,837
============= =============
Source: PharmaFrontiers Corp.

[frank55]

PharmaFrontiers Changes Name to Opexa Therapeutics; New Ticker Symbol is OPXA


THE WOODLANDS, Texas--(BUSINESS WIRE)--June 19, 2006--

Additional Proposals Approved by Shareholders Includes
1-for-10 Reverse Stock Split
Opexa Therapeutics, (OTCBB: OPXA), a company involved in the development and commercialization of cell therapies, today announced that its stockholders at the Company's 2006 annual meeting on June 15 ratified the change of the Company's name from PharmaFrontiers Corp. to Opexa Therapeutics, Inc. and effected a 1-for-10 (1:10) reverse split of its common stock. In addition the shareholders ratified the election of David B. McWilliams, Scott B. Seaman, Gregory H. Bailey and David Hung to the Company's board of directors and approved an amendment to the Company's June 2004 Compensatory Stock Option Plan.

The new ticker symbol, OTCBB:OPXA, goes into effect today, June 19, 2006 and the stock trading will give effect to the reverse split also effective today.

Additionally, the Company's transfer agent, Continental Stock Transfer & Trust Co., will send instructions to the Company's shareholders regarding exchange of their old certificates for the new stock certificates.

The company also announced the retirement of C. William Rouse as chief financial officer. Lynne Hohlfeld, vice president, finance at Opexa, will assume the position of chief financial officer as of June 30, 2006.

David McWilliams, chief executive officer of Opexa, commented on the recent developments. "Management believes that these proposals will be critical to the Company's growth and we are very pleased that our shareholders concurred. The reverse stock split will be instrumental in our plan to apply for a NASDAQ listing. The make-up of our board of directors comprises a very strategic cross-section of highly scientific, financially savvy and business-oriented professionals who can guide the company through the process of commercializing our therapeutics. Finally, we are very excited to have adopted the name, Opexa Therapeutics. Opexa was the original developer of Tovaxin(TM), which is being studied for the treatment of multiple sclerosis, and as such represents our past. Opexa also, and, most importantly, represents our future, which is the development of our novel T-cell and stem cell technologies."

Continued Mr. McWilliams, "I would also like to thank Bill Rouse for working tirelessly to help move the Company to its current state. His financial acumen has been a critical component in putting the Company on the firmest financial footing we have ever known."

About Opexa Therapeutics

Opexa Therapeutics' strategy is to develop and commercialize cell therapies to treat several major disease areas such as multiple sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions. Opexa has exclusive license from Baylor College of Medicine for individualized cell therapies and has initiated the FDA Phase IIb clinical trial to evaluate effectiveness in treating MS. The company also holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The company also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. For more information, visit Opexa Therapeutics' website at www.opexatherapeutics.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about Opexa Therapeutics' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Opexa Therapeutics' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause Opexa Therapeutics' actual results to be materially different from any future results expressed or implied by such forward-looking statements. Opexa Therapeutics undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Opexa Therapeutics, Inc.